Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluticasone furoate/umeclidinium/vilanterol - GSK/Innoviva/Theravance Biopharma

Next Previous
Drug Profile

Fluticasone furoate/umeclidinium/vilanterol - GSK/Innoviva/Theravance Biopharma

Alternative Names: BREO ELLIPTA/RELVAR; Elebrato Ellipta; FF/UMEC/VI; fluticasone furoate+ vilanterol + umeclidinium bromide; Fluticasone Furoate/Umeclidinium/Vilanterol Trifenatate; Fluticasone furoate/vilanterol/umeclidinium; GSK 2834425; GW 685698/GSK 573719/GW 642444; GW685698 + GW642444 + GSK573719; ICS/LABA/LAMA - GSK; ICS/LAMA/LABA - GSK; RELVAR/BREO ELLIPTA; TRELEGY ELLIPTA; Trelegy Ellipta; UMEC/VI/FF; Umeclidinium/fluticasone furoate/vilanterol; Umeclidinium/vilanterol/fluticasone furoate; Vilanterol/fluticasone furoate/umeclidinium; Vilanterol/umeclidinium/fluticasone furoate

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GSK; Innoviva; Theravance Biopharma
  • Class Androstadienes; Anti-inflammatories; Antiasthmatics; Benzhydryl compounds; Bronchodilators; Chlorobenzenes; Ethers; Glucocorticoids; Phenols; Quinuclidines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 09 Jan 2025 Phase III development for Asthma (Treatment-experienced) is ongoing China (Inhalation)
  • 09 Jan 2025 Preregistration development for Asthma is ongoing in European Union
  • 05 Aug 2024 GlaxoSmithKline completes phase III trial in Asthma (Treatment-experienced) in China (Inhalation) (NCT04937387)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top